What are the Treatments for Polycythemia Vera?
What are the Treatments for Polycythemia Vera?
Polycythemia vera (PV) is a slow-growing blood cancer in which the bone marrow makes too many red blood cells. These excess cells thicken blood, slowing its flow, which may cause serious complications, such as blood clots.
The goal of treatment is to reduce the thickness of the blood and prevent bleeding and clotting. A variety of treatments are available, including medications, phlebotomy, and other procedures.
Risk-Based Treatment Approach
Treatment for PV is based on whether a person is considered low-risk or high-risk:
Low-risk: Under 60 years old with no history of blood clots
High-risk: Age 60 or older and/or history of thrombosis
This risk classification helps determine which therapies are appropriate and how aggressively the condition should be managed
Phlebotomy
Phlebotomy is the primary treatment for low-risk PV. It involves drawing blood, much like a donation, to reduce red blood cell levels and achieve a hematocrit target of less than 45%. This reduces the chance of blood clots and cardiovascular events.
One unit (500 mL) of blood typically lowers hematocrit by about 3% in an average-sized adult.
Men may tolerate 1.5–2 units per week; women, the elderly, or those with heart conditions may tolerate 0.5 units.
The goal is to create a mild iron-deficient state to slow red blood cell production.
Avoid iron supplements, as they counteract the effects of phlebotomy.
Low-Dose Aspirin
Low-dose aspirin (40–100 mg once or twice daily) is recommended to reduce clot risk by preventing platelets from sticking together. However:
People with platelet counts above 1 million/microliter may be at higher risk of bleeding due to acquired von Willebrand syndrome and should avoid aspirin.
Aspirin is also helpful for aspirin-responsive microvascular symptoms, like headaches or burning sensations in the skin.
Cytoreductive Therapy (for High-Risk Patients)
In high-risk patients, medication is added to reduce blood cell production:
Hydroxyurea (Hydrea) is a first-line therapy due to its effectiveness, safety, and low cost. The starting dose is 15 mg/kg daily, aiming for platelet levels between 100,000 and 400,000/microliter without causing anemia or neutropenia.
Pegylated interferon or busulfan may be used if hydroxyurea is not tolerated.
Ruxolitinib (Jakafi): A JAK inhibitor approved by the FDA for patients who don’t respond to or can’t tolerate hydroxyurea. It can reduce red blood cells and improve symptoms. Many patients on ruxolitinib achieve complete hematologic remission.
Other cytoreductive options include anagrelide, radioactive phosphorus, pipobroman, and investigational drugs in clinical trials.
Radiation Therapy and Surgery
Radiation therapy is rarely used today due to long-term risks but may be considered for older patients who cannot tolerate other therapies. It can suppress the bone marrow's ability to produce blood cells. However, it's less commonly used today due to the potential long-term side effects.
Surgical procedures are considered for complications involving the spleen or liver blood flow.
Clinical Trials
Clinical trials provide access to new treatments not yet available in standard care. They are not just for advanced disease. Many studies are evaluating new therapies for PV, including alternatives to current medications aimed at better symptom control.
To learn more about your polycythemia vera clinical trial options, visit HealthTree for polycycthemia vera Clinical Trial Finder. Utilize the advanced filter option to locate trials that you are eligible to participate in. You can create a HealthTree account to favorite your top trial options so you can discuss them with your specialist.
Managing Symptoms and Complications
Pruritus (itching): Treated initially with antihistamines or SSRIs. If not effective, options include interferon or JAK inhibitors.
Painful splenomegaly or recurrent splenic infarcts: May require splenectomy (surgical removal of the spleen).
Budd-Chiari syndrome (blocked liver veins): May need surgical procedures like TIPS or portosystemic shunts.
Supportive care should also focus on heart and vascular health, including managing blood pressure, quitting smoking, exercising regularly, and maintaining a healthy weight.
Stay Updated on the Latest Polycythemia Vera News
Are you interested in learning more about polycythemia vera? Click on the button below to read PV news articles.
Source: